NasdaqGM:XENEBiotechs
Assessing Xenon Pharmaceuticals (XENE) Valuation After New Phase 3 Azetukalner Epilepsy Data
Xenon Pharmaceuticals (XENE) is back in focus after presenting Phase 3 X-TOLE2 data for azetukalner in adults with focal onset seizures, supported by long term X-TOLE extension and real world no titration feedback.
See our latest analysis for Xenon Pharmaceuticals.
The latest clinical update has arrived after a strong few quarters for the stock, with a 36.87% 90 day share price return and a 46.63% 1 year total shareholder return that suggest momentum has been building around Xenon’s lead...